tiprankstipranks
Advertisement
Advertisement

EVMN Stock Latest News

Clear Street sees attractive point into Evommune after selloff
The FlyClear Street sees attractive point into Evommune after selloff
6d ago
EVMN
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
PremiumCompany Announcements
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
21d ago
EVMN
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
PremiumCompany Announcements
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
21d ago
EVMN
Septerna price target lowered to $45 from $52 at Guggenheim
PremiumThe Fly
Septerna price target lowered to $45 from $52 at Guggenheim
21d ago
EVMN
SEPN
Evommune price target lowered to $26 from $55 at Morgan Stanley
PremiumThe Fly
Evommune price target lowered to $26 from $55 at Morgan Stanley
22d ago
EVMN
Evommune downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyEvommune downgraded to Neutral from Buy at H.C. Wainwright
22d ago
EVMN
Evommune price target lowered to $28 from $53 at Clear Street
Premium
The Fly
Evommune price target lowered to $28 from $53 at Clear Street
23d ago
EVMN
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
Premium
The Fly
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
23d ago
VZ
CRM
Evommune downgraded to Market Perform from Outperform at William Blair
PremiumThe Fly
Evommune downgraded to Market Perform from Outperform at William Blair
23d ago
EVMN
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
PremiumCompany Announcements
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
23d ago
8K
EVMN
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
PremiumThe Fly
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
23d ago
EVMN
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
PremiumThe Fly
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
30d ago
ABBV
APGE
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
PremiumThe FlyCanaccord sees potential Apogee buyout as ‘huge win’ for sector
1M ago
ABBV
APGE
Evommune Stockholders Reelect Directors and Ratify Auditor
Premium
Company Announcements
Evommune Stockholders Reelect Directors and Ratify Auditor
2M ago
8K
EVMN
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
Premium
Ratings
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
2M ago
EVMN
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
PremiumRatings
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
2M ago
EVMN
Evommune price target raised to $55 from $54 at Morgan Stanley
PremiumThe Fly
Evommune price target raised to $55 from $54 at Morgan Stanley
2M ago
EVMN
Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts
PremiumRatings
Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts
3M ago
EVMN
Evommune reports Q1 EPS (64c), consensus (71c)
PremiumThe Fly
Evommune reports Q1 EPS (64c), consensus (71c)
3M ago
EVMN
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
PremiumCompany AnnouncementsEvommune Highlights Q1 Results and Advancing Inflammation Pipeline
3M ago
8K
EVMN
Evommune initiated with a Buy at Stifel
Premium
The Fly
Evommune initiated with a Buy at Stifel
3M ago
EVMN
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis
Premium
Company Announcements
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis
3M ago
EVMN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >